Wave Life Sciences is a biotechnology company focused on delivering transformational therapies for patients with serious and genetically-defined diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM. For this purpose, the clinical-stage genetic medicines company designs and produces stereopure oligonucleotides with its proprietary discovery and drug development platform.
On March 29, Wave announced its data from the Phase 1b/2a PRECISION-HD2 and PRECISION-HD1 trials evaluating investigational treatments in Huntington’s disease (WVE-120102 and WVE-120101). In the PRECISION-HD2 trials, results from all participants show not statistically significant change or else modest reductions in mutant huntingtin protein (mHTT) versus placebo after single or multiple doses of WVE-120102. For that reason, Wave will stop clinical development of WVE-120102. Results in all participants from the PRECISION-HD1 core trial are similar to those in PRECISION-HD2. Given these results, as well as current understanding of the limitations of Wave’s first-generation candidates, the company will also stop clinical development of WVE-120101.
Wave is continuing working on WVE-003, a next-generation investigational drug designed to selectively lower mHTT by targeting a specific single nucleotide polymorphism (SNP3). In addition, these clinical candidates have also been optimized with pharmacodynamic and pharmacokinetic insights from in vivo models. Wave expects that its expected cash from collaborations and its existing cash will enable to fund its capital and operating requirements.
Wave’s stock price slumped 24.85% this year.